Clinical trial
A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy - Dornase Alfa (Dnase)
NCT06350474 is registered in ClinicalTrials.gov with Nicole Hamblett as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Master Protocol to Test the Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy - Dornase Alfa (Dnase)
- Lead sponsor
- Nicole Hamblett
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- August 25, 2020
- Completion date
- July 11, 2022
- Enrollment
- 477 (actual)
- Sites
- 81
Conditions
As the registry lists them; a condition with its own page is linked.